Current Perspective on HPV-Associated Oropharyngeal Carcinomas and the Role of p16 as a Surrogate Marker of High-Risk HPV

Česká verzia

Authors: Dominik Gurín ¹; Marek Slávik ²; Tetiana Shatokhina ¹; Tomáš Kazda ^2,3; Jiří Šána ^3,4; Ondřej Slabý ^3,4; Markéta Hermanová
Authors place of work: I. ústav patologie, LF MU a FN u sv. Anny v Brně ¹; Klinika radiační onkologie, LF MU a Masarykův onkologický ústav, Brno ²; CEITEC – Středoevropský technologický institut, MU, Brno ³; Klinika komplexní onkologické péče, LF MU a Masarykův onkologický ústav, Brno ⁴
Published in the journal: Klin Onkol 2019; 32(4): 252-260
Category: Review
doi: https://doi.org/10.14735/amko2019252

Summary

Background: The incidence of oropharyngeal carcinomas associated with human papillomavirus (HPV) is continuously increasing. HPV-positive and -negative oropharyngeal carcinomas have different epidemiological, clinical, and molecular features, with HPV-positive tumors having a better response to treatment and better prognosis. An adequate staging system for HPV-related oropharyngeal carcinomas is needed, as the American Joint Committee on Cancer 7^th Edition did not consider their unique biological behavior. At present, oropharyngeal carcinomas are subdivided into p16 positive and p16 negative tumors, based on their expression of p16, a surrogate marker of high-risk HPV.

Purpose: This review summarizes current knowledge of HPV-associated oropharyngeal carcinomas with emphasis on their molecular features and histopathology, as well as summarizes and compares HPV detection methods and genotyping techniques. This review also describes the prognostic significance of p16 expression in these tumors and significant changes in the staging of oropharyngeal carcinomas based on p16 expression, together with the justifications for these changes. Finally, this review reports the recommendations of the College of American Pathologists for testing HPV in head and neck cancers, supported by the American Society of Clinical Oncology.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Submitted: 18. 2. 2019

Accepted: 30. 5. 2019

Keywords:

human papillomavirus – p16 – oropharyngeal cancer – squamous cell carcinoma – TNM staging

Zdroje

1. Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003; 260 (9): 502–508. doi: 10.1007/s00405-003-05 81-3.

2. Martín-Hernán F, Sánchez-Hernández JG, Cano J et al. Oral cancer, HPV infection and evidence of sexual transmission. Med Oral Patol Oral Cir Bucal 2013; 18 (3): e439–e444. doi: 1 0.4317/medoral.18419.

3. Hammarstedt L, Lindquist D, Dahlstrand H et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006; 119 (11): 2620–2623. doi: 10.1002/ijc.22177.

4. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110 (7): 1429–1435. doi: 10.1002/cncr.22963.

5. Chaturvedi AK, Engels EA, Anderson WF et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26 (4): 612–619. doi: 10.1200/JCO.2007.14.1713.

6. Näsman A, Nordfors C, Holzhauser S et al. Incidence of human papillomavirus positive tonsillar and base of tongue carcinoma: a stabilisation of an epidemic of viral induced carcinoma? Eur J Cancer 2015; 51 (1): 55–61. doi: 10.1016/j.ejca.2014.10.016.

7. Ramquist T, Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 2011; 31 (5): 1515–1519.

8. Adelstein D, Gillison ML, Pfister DG et al. NCCN guidelines insights: head and neck cancers, version 2.2017. J Natl Compr Canc Netw 2017; 15 (6): 761–770. doi: 10.6004/jnccn.2017.0101.

9. Chaturvedi AK, Engels EA, Pfeiffer RM et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29 (32): 4294–4301. doi: 10.1200/JCO.2011.36.4596.

10. Münger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89 (2): 213–228.

11. Chaturvedi AK, Anderson WF, Lortet-Tieulent J et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31 (36): 4550–4559. doi: 10.1200/JCO.2013.50.3870.

12. Husain N, Neyaz A. Human papillomavirus associated head and neck squamous cell carcinoma: controversies and new concepts. J Oral Biol Craniofac Res 2017; 7 (3): 198–205. doi: 10.1016/j.jobcr.2017.08.003.

13. Jung AC, Briolat J, Millon R et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer 2010; 126 (8): 1882–1894. doi: 10.1002/ijc.24911.

14. Straetmans JMJAA, Olthof N, Mooren J et al. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope 2009; 119 (10): 1951–1957. doi: 10.1002/lary.20593.

15. El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 2012; 34 (4): 459–461. doi: 10.1002/hed. 21974.

16. Sellers WR, Rodgers JW, Kaelin WG. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci USA 1995; 92 (25): 11544–11548. doi: 10.1073/pnas.92.25.11544.

17. Witkiewicz AK, Knudsen KE, Dicker AP et al. The meaning of p16 (ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 2011; 10 (15): 2497–2503. doi: 10.4161/cc.10.15.16776.

18. Münger K, Werness BA, Dyson N et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8 (13): 4099–4105.

19. Takeuchi S, Takahashi A, Motoi N et al. Intrinsic cooperation between p16INK4a and p21Waf1/Cip1 in the onset of cellular senescence and tumor suppression in vivo. Cancer Res 2010; 70 (22): 9381–9390. doi: 10.1158/0008-5472.CAN-10-0801.

20. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13 (12): 1501–1512. doi: 10.1101/gad.13.12.1501.

21. Jirawatnotai S, Hu Y, Michowski W et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011; 474 (7350): 230–234. doi: 10.1038/nature10155.

22. Dok R, Kalev P, Van Limbergen EJ et al. p16INK4a impairs homologous recombination-mediated DNA repair in human papillomavirus-positive head and neck tumors. Cancer Res 2014; 74 (6): 1739–1751. doi: 10.1158/0008-5472.CAN-13-2479.

23. van Houten VM, Snijders PJ, van Den Brekel MW et al. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001; 93 (2): 232–235. doi: 10.1002/ijc.1313.

24. Shinohara S, Kikuchi M, Tona R et al. Prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas. Jpn J Clin Oncol 2014; 44 (3): 232–240. doi: 10.1093/jjco/hyt223.

25. Linge A, Lohaus F, Löck S et al. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiother Onco 2016; 121 (3): 364–373. doi: 10.1016/j.radonc.2016.11.008.

26. Gurin D, Slavik M, Hermanova M et al. Prognostic impact of combined immunoprofiles in oropharyngeal squamous cell carcinoma patients with respect to AJCC 8th edition. J Oral Pathol Med 2018; 47 (9): 864–872. doi: 10.1111/jop.12772.

27. Slavik M, Shatokhina T, Sana J et al. Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: impact on outcomes of intensity-modulated radiation therapy. Head Neck 2019; 41 (4): 940–949. doi: 10.1002/hed.25533.

28. Stransky N, Egloff AM, Tward AD et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333 (6046): 1157–1160. doi: 10.1126/science.1208130.

29. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363 (1): 24–35. doi: 10.1056/NEJMoa0912217.

30. Gildener-Leapman N, Lee J, Ferris RL. Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol 2014; 50 (9): 780–784. doi: 10.1016/j.oraloncology.2013.09.010.

31. Mirghani H, Amen F, Blanchard P et al. Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer 2015; 136 (7): 1494–1503. doi: 10.1002/ijc.28847.

32. Shi W, Kato H, Perez-Ordonez B. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27 (36): 6213–6221. doi: 10.1200/JCO.2009.23.1670.

33. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010; 116 (9): 2166–2173. doi: 10.1002/cncr.25033.

34. Smeets SJ, Hesselink AT, Speel EJ et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121 (11): 2465–2472. doi: 10.1002/ijc.22980.

35. Sedghizadeh PP, Billington WD, Paxton D et al. Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis. Oral Oncol 2016; 54: 15–27. doi: 10.1016/j.oraloncology.2016.01.002.

36. Fakhry C, Lacchetti C, Rooper LM et al. Human papillomavirus testing in head and neck carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. J Clin Oncol 2018; 36 (31): 3152–3161. doi: 10.1200/JCO.18.00684.

37. Perrone F, Gloghini A, Cortelazzi B et al. Isolating p16-positive/HPV-negative oropharyngeal cancer: an effort worth making. Am J Surg Pathol 2011; 35 (5): 774–777; author reply 777–778. doi: 10.1097/PAS.0b013e3182116 a45.

38. Ukpo OC, Flanagan JJ, Ma XJ et al. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol 2011; 35 (9): 1343–1350. doi: 10.1097/PAS.0b013e318220e59d.

39. Anonym. TCGA releases head and neck cancer data. Cancer Discov 2015; 5 (4): 340–341. doi: 10.1158/2159-8290.CD-NB2015-024.

40. Jordan RC, Lingen MW, Perez-Ordonez B et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 2012; 36 (7): 945–954. doi: 10.1097/PAS.0b013e318253a2d1.

41. Fonmarty D, Cherriere S, Fleury H et al. Study of the concordance between p16 immunohistochemistry and HPV-PCR genotyping for the viral diagnosis of oropharyngeal squamous cell carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 2015; 132 (3): 135–139. doi: 10.1016/j.anorl.2015.01.003.

42. Lewis J, Ukpo OC, Ma XJ et al. Transcriptionally-active high-risk human papillomavirus is rare in oral cavity and laryngeal/hypopharyngeal squamous cell carcinomas– a tissue microarray study utilizing E6/E7 mRNA in situ hybridization. Histopathology 2012; 60 (6): 982–991. doi: 10.1111/j.1365-2559.2011.04169.x.

43. Bishop JA, Ma XJ, Wang H et al. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol 2012; 36 (12): 1874–1882. doi: 10.1097/PAS.0b013e318265fb2b.

44. Kerr DA, Arora KS, Mahadevan KK et al. Performance of a branch chain RNA in situ hybridization assay for the detection of high-risk human papillomavirus in head and neck squamous cell carcinoma. Am J Surg Pathol 2015; 39 (12): 1643–1652. doi: 10.1097/PAS.0000000000000516.

45. Mirghani H, Casiraghi O, Amen F et al. Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice. Mod Pathol 2015; 28 (12): 1518–1527. doi: 10.1038/modpathol.2015.113.

46. Prigge ES, Arbyn M, von Knebel Doeberitz et al. Diagnostic accuracy of p16INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis. Int J Cancer 2017; 140 (5): 1186–1198. doi: 10.1002/ijc.30516.

47. Taberna M, Mena M, Pavón MA et al. Human papillomavirus-related oropharyngeal cancer. Ann Oncol 2017; 28 (10): 2386–2398. doi: 10.1093/annonc/mdx304.

48. Lydiatt WM, Patel SG, O’Sullivan B et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67 (2): 122–137. doi: 10.3322/caac.21389.

49. Goodman MT, Saraiya M, Thompson TD et al. Human papillomavirus genotype and oropharynx cancer survival in the United States of America. Eur J Cancer 2015; 51 (18): 2759–2767. doi: 10.1016/j.ejca.2015.09.005.

50. Castellsagué X, Alemany L, Quer M et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 2016; 108 (6): djv403. doi: 10.1093/jnci/djv403.

51. Lace MJ, Anson JR, Klingelhutz AJ et al. Human papillomavirus (HPV) type 18 induces extended growth in primary human cervical, tonsillar, or foreskin keratinocytes more effectively than other high-risk mucosal HPVs. J Virol 2009; 83 (22): 11784–11794. doi: 10.1128/JVI.01370-09.

52. Arends MJ, Wyllie AH, Bird CC. Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16. Br J Cancer 1995; 72 (3): 646–649. doi: 10.1038/bjc.1995.388.

53. Villa LL, Schlegel R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virol 1991; 181 (1): 374–377. doi: 10.1016/0042-6822 (91) 90507-8.

54. Bratman SV, Bruce JP, O’Sullivan B et al. Human papillomavirus genotype association with survival in head and neck squamous cell carcinoma. JAMA Oncol 2016; 2 (6): 823–826. doi: 10.1001/jamaoncol.2015.6587.

55. Varier I, Keeley BR, Krupar R et al. Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes. Head Neck 2016; 38 (9): 1330–1337. doi: 10.1002/hed.24442.

56. Mazul AL, Rodriguez-Ormaza N, Taylor JM et al. Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma. Oral Oncol 2016; 61: 98–103. doi: 10.1016/j.oraloncology.2016.08.019.

57. Rietbergen MM, Brakenhoff RH, Bloemena E et al. Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials. Ann Oncol 2013; 24 (11): 2740–2745. doi: 10.1093/annonc/mdt319.

58. Mirghani H, Blanchard P. Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand? Clin Transl Radiat Oncol 2017; 8: 4–11. doi: 10.1016/j.ctro.2017.10.005.

59. Lewis JS Jr., Khan RA, Masand RP et al. Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma – a prospective cohort and interobserver variability study. Histopathology 2012; 60 (3): 427–436. doi: 10.1111/j.1365-2559.2011.04092.x.

60. Lewis JS Jr., Scantlebury JB, Luo J et al. Tumor cell anaplasia and multinucleation are predictors of disease recurrence in oropharyngeal squamous cell carcinoma, including among just the human papillomavirus-related cancers. Am J Surg Pathol 2012; 36 (7): 1036–1046. doi: 10.1097/PAS.0b013e3182583678.

61. Amin MB, Edge S, Greene F et al (eds). AJCC cancer staging manual. 8th ed. Springer International Publishing 2017.

62. Goldenberg D, Begum S, Westra WH et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 2008; 30 (7): 898–903. doi: 10.1002/hed.20796.

63. Malm IJ, Fan CJ, Yin LX et al. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. Cancer 2017; 123 (10): 1768–1777. doi: 10.1002/cncr.30512.

64. Smitha T, Dinakaran A. Modifications and recent updates in the 8th edition of tumor node metastasis staging pertaining to oropharynx and oral cavity. J Oral Maxillofac Pathol 2018; 22 (1): 6–8. doi: 10.4103/jomfp.JOMFP_59_18.

65. Keane FK, Chen YH, Tishler RB et al. Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck 2016; 38 (10): 1530–1538. doi: 10.1002/hed.24470.

66. Edge SB, American Joint Committee on Cancer (ed). AJCC cancer staging manual. 7th ed. New York: Springer 2010.

67. Horne ZD, Glaser SM, Vargo JA et al. Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. Cancer 2016; 122 (13): 2021–2030. doi: 10.1002/cncr.30021.

68. Huang SH, Xu W, Waldron J et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol 2015; 33 (8): 836–845. doi: 10.1200/JCO.2014.58.6412.

69. Mizumachi T, Homma A, Sakashita T et al. Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan. International J Clin Oncol 2017; 22 (4): 682–689. doi: 10.1007/s10147-017-1107-0.

70. Ward MJ, Mellows T, Harris S et al. Staging and treatment of oropharyngeal cancer in the human papillomavirus era. Head Neck 2015; 37 (7): 1002–1013. doi: 10.1002/hed.23697.

71. O’Sullivan B, Huang SH, Su J al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016; 17 (4): 440–451. doi: 10.1016/S1470-2045 (15) 00560-4.

72. Würdemann N, Wagner S, Sharma SJ et al. Prognostic impact of AJCC/UICC 8th edition New Staging rules in oropharyngeal squamous cell carcinoma. Front Oncol 2017; 7: 129. doi: 10.3389/fonc.2017.00 129.

73. Zhan KY, Eskander A, Kang SY et al. Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base. Oral Oncol 2017; 73: 152–159. doi: 10.1016/j.oraloncology.2017.08.020.

74. Panwar A, Interval E, Lydiatt WM. Emergence of a novel staging system for oropharyngeal squamous cell carcinoma based on HPV status. Oncology (Williston Park) 2017; 31 (12): e33–e40.

75. Haughey BH, Sinha P, Kallogjeri D et al. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral Oncol 2016; 62: 11–19. doi: 10.1016/j.oraloncology.2016.09.004.

76. Sinha P, Kallogjeri D, Gay H et al. High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral Oncol 2015; 51 (5): 514–520. doi: 10.1016/j.oraloncology.2015.02.098.

77. Hobelmann KC, Topf MC, Bar-Ad V et al. AJCC-8ed nodal staging does not predict outcomes in surgically managed HPV-associated oropharyngeal cancer. Oral Oncol 2018; 82: 138–143. doi: 10.1016/j.oraloncology.2018.05.016.

78. Lewis JS Jr., Beadle B, Bishop JA et al. Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists. Arch Pathol Lab Med 2018; 142 (5): 559–597. doi: 10.5858/arpa.2017-0286-CP.